A traditional Chinese medicine composition for promoting blood circulation and unblocking meridians and its application in preparing medicine for treating stroke

Abstract

The present invention discloses a traditional Chinese medicine composition for promoting blood circulation and unblocking meridians, and its use in preparing a medicament for treating cerebral stroke. The traditional Chinese medicine composition is prepared from astragalus root, angelica root, earthworm, millettia reticulata, salvia miltiorrhiza, safflower, mulberry branch, earthworm, processed polygonum multiflorum, cornus officinalis, Morinda officinalis, and Eucommia bark. The present invention optimizes the compatibility based on a traditional old prescription to obtain a new traditional Chinese medicine formula, which has the effects of invigorating qi and promoting blood circulation, nourishing the liver and kidneys, and removing blood stasis and unblocking meridians. It repairs brain damage caused by cerebral stroke, alleviates neurological dysfunction and brain tissue inflammation, is safe, has no drug-induced liver damage toxicity, and cooperates with Western medicine precision medicine to significantly improve the therapeutic effect of cerebral stroke, improve patients' clinical symptoms, and promote the recovery of neurological function, providing a new integrated Chinese and Western medicine treatment strategy for clinical practice.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine pharmaceuticals, and in particular to a traditional Chinese medicine composition for promoting blood circulation and unblocking meridians and its application in preparing a medicine for treating cerebral apoplexy. Background Art

[0002] Stroke is a serious neurological disease that is mainly divided into two categories: ischemic stroke (caused by cerebral blood vessel obstruction) and hemorrhagic stroke (caused by cerebral blood vessel rupture). It usually causes localized or widespread damage to the brain, leading to symptoms such as limb paralysis, speech disorders, and cognitive decline. Acute cerebral infarction (also known as acute ischemic stroke) is the most common type of ischemic stroke and falls under the category of "stroke disease" in Traditional Chinese Medicine. It is believed that it is caused by liver and kidney deficiency and qi and blood deficiency in old age, coupled with abnormal diet and improper work and rest, which lead to internal generation of phlegm and blood stasis, poor circulation of qi and blood, and obstruction of blood vessels. Traditional Chinese Medicine syndrome differentiation classifies it as a syndrome of deficiency of the root and excess of the symptoms. The symptoms are excessive wind and fire, while the root is liver and kidney deficiency and qi and blood deficiency. Different Chinese herbal decoctions can be used for treatment according to different syndrome types. Clinically, the "qi deficiency and blood stasis type" is more common in acute cerebral infarction.

[0003] Western medicine treatment for acute cerebral infarction primarily relies on thrombolytics, antiplatelet drugs, anticoagulants, and supportive therapies to quickly restore cerebral blood flow and minimize brain damage. However, this approach faces challenges such as time window limitations, side effects, and the risk of recurrence. In recent years, the integrated treatment strategy of traditional Chinese and Western medicine for stroke has gained increasing attention. This approach aims to leverage the precise diagnosis and acute management capabilities of Western medicine with the long-term conditioning and rehabilitation-promoting effects of Traditional Chinese Medicine to achieve better clinical outcomes. Current research focuses on integrating the principles of TCM syndrome differentiation and treatment with Western precision medicine to develop a scalable and replicable treatment plan. Summary of the Invention

[0004] In order to solve the above problems existing in the prior art, the present invention provides a traditional Chinese medicine composition for promoting blood circulation and unblocking meridians and its use in preparing a medicine for treating stroke.

[0005] The first object of the present invention is to provide a Chinese medicine composition for promoting blood circulation and unblocking meridians.

[0006] The second object of the present invention is to provide the use of the traditional Chinese medicine composition and / or its extract in the preparation of a medicine for treating stroke.

[0007] The third object of the present invention is to provide the use of the traditional Chinese medicine composition and / or its extract in the preparation of a drug for repairing brain damage caused by stroke.

[0008] The fourth object of the present invention is to provide the use of the traditional Chinese medicine composition and / or its extract in the preparation of a drug for alleviating neurological dysfunction and / or brain tissue inflammation caused by stroke.

[0009] The fifth object of the present invention is to provide the use of the traditional Chinese medicine composition and / or its extract as a synergist of Western medicine treatment in the preparation of a drug for treating stroke.

[0010] The sixth object of the present invention is to provide an oral medicine for treating stroke.

[0011] The seventh object of the present invention is to provide a method for preparing an oral medicine for treating stroke.

[0012] In order to achieve the above object, the present invention is implemented through the following scheme:

[0013] A traditional Chinese medicine composition for promoting blood circulation and unblocking meridians is prepared, by weight, from 35 to 45 parts of astragalus, 15 to 20 parts of angelica root, 15 to 20 parts of earthworm, 30 to 38 parts of millettia reticulata, 30 to 38 parts of salvia miltiorrhiza, 10 to 16 parts of safflower, 30 to 38 parts of morus, 10 to 16 parts of earthworm, 30 to 38 parts of processed polygonum multiflorum, 15 to 20 parts of cornus officinalis, 15 to 20 parts of morinda officinalis and 15 to 20 parts of eucommia.

[0014] Preferably, the medicine is made from 35 parts of astragalus, 15 parts of angelica root, 15 parts of earthworm, 30 parts of millettia reticulata, 30 parts of salvia miltiorrhiza, 10 parts of safflower, 30 parts of mulberry twig, 10 parts of earthworm, 30 parts of processed polygonum multiflorum, 15 parts of cornus officinalis, 15 parts of morinda officinalis and 15 parts of eucommia.

[0015] Preferably, the medicine is made from 40 parts of astragalus, 18 parts of angelica root, 18 parts of earthworm, 35 parts of millettia reticulata, 35 parts of salvia miltiorrhiza, 14 parts of safflower, 35 parts of mulberry twig, 14 parts of earthworm, 35 parts of processed polygonum multiflorum, 18 parts of cornus officinalis, 18 parts of morinda officinalis and 18 parts of eucommia.

[0016] Preferably, the medicine is made from 45 parts of astragalus, 20 parts of angelica root, 20 parts of earthworm, 38 parts of millettia reticulata, 38 parts of salvia miltiorrhiza, 16 parts of safflower, 38 parts of mulberry twig, 16 parts of earthworm, 38 parts of processed polygonum multiflorum, 20 parts of cornus officinalis, 20 parts of morinda officinalis and 20 parts of eucommia.

[0017] The pharmacological properties, functions and indications of each Chinese medicinal ingredient in the Chinese medicinal composition for promoting blood circulation and unblocking meridians are as follows:

[0018] Astragalus: The dried root of Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge.) Hsiao or Astragalus membranaceus (Fisch.) Bge. of the Leguminosae family; sweet, slightly warm; enters the lung and spleen meridians; tonifies qi and raises yang, consolidates the exterior and stops sweating, promotes diuresis and reduces swelling, promotes fluid production and nourishes blood, relieves stagnation and arthritis, expels toxins and discharges pus, and heals sores and promotes tissue regeneration; used for qi deficiency and fatigue, poor appetite and loose stools, sinking of qi in the middle, chronic diarrhea and prolapse of the anus, bloody stool and metrorrhagia, spontaneous sweating due to exterior deficiency, qi deficiency and edema, internal heat and thirst, blood deficiency and sallow complexion, hemiplegia, pain and numbness, and carbuncles that are difficult to heal and that do not heal for a long time.

[0019] Earthworm: The dried body of Pheretima aspergillum (E.Perrier), Pheretima vulgaris Chen, Pheretima guillelmi (Michaelsen), or Pheretima pectinifera Michaelsen, animals of the family Lumbricidae; salty, cold; enters the liver, spleen, and bladder meridians; clears heat and calms the nerves, dredges the meridians, relieves asthma, and is a diuretic; used for high fever and coma, epilepsy and convulsions, joint pain, limb numbness, hemiplegia, lung heat and cough, edema and oliguria.

[0020] Millettia reticulata: Dried vine stem of Spatholobus suberectus Dunn, a plant of the Leguminosae family; bitter, sweet, and warm; enters the Liver and Kidney meridians; promotes blood circulation and replenishes blood, regulates menstruation and relieves pain, relaxes tendons and activates collaterals; used for irregular menstruation, dysmenorrhea, amenorrhea, rheumatic pain, numbness and paralysis, and blood deficiency and sallow complexion.

[0021] Salvia miltiorrhiza: The dried root and rhizome of Salvia miltiorrhiza Bge., a plant of the Lamiaceae family; bitter, slightly cold; enters the heart and liver meridians; promotes blood circulation and removes blood stasis, promotes menstruation and relieves pain, clears the heart and relieves restlessness, cools blood and eliminates carbuncles; used for chest pain, abdominal pain, flank pain, accumulation of masses, pain due to heat, restlessness and insomnia, irregular menstruation, dysmenorrhea and amenorrhea, and swollen and painful sores.

[0022] Safflower: Dried flowers of Carthamus tinctorius L., a plant of the Asteraceae family; pungent and warm; enters the heart and liver meridians; promotes blood circulation and menstruation, dissipates blood stasis and relieves pain; used for amenorrhea, dysmenorrhea, retained lochia, lumps and masses, chest pain, abdominal pain due to blood stasis, stabbing pain in the chest and ribs, injuries from falls, and swollen and painful sores.

[0023] Angelica root: The lateral root (root) of the dried root of Angelica sinensis (Oliv.) Diels of the Umbelliferae family is 0.3 to 1 cm in diameter, thick at the top and thin at the bottom, mostly twisted, with a few root hairs; it tastes sweet and spicy, and is warm in nature; it enters the liver, heart, and spleen meridians; it replenishes blood, promotes blood circulation, removes blood stasis, and moistens the intestines and promotes bowel movements.

[0024] Morinda officinalis: The dried root of Morinda officinalis, a plant of the Rubiaceae family; sweet, pungent, and slightly warm; enters the kidney and liver meridians; tonifies kidney yang, strengthens bones and muscles, and dispels rheumatism; used for impotence and spermatorrheumatic emission, cold speech and infertility, irregular menstruation, cold pain in the lower abdomen, rheumatic pain, and weakness of bones and muscles.

[0025] Eucommia ulmoides: dried bark of Eucommia ulmoides Oliv., a plant of the Eucommia family; sweet, warm; enters the liver and kidney meridians; tonifies the liver and kidneys, strengthens the bones and tendons, and stabilizes the fetus; used for liver and kidney deficiency, soreness of the waist and knees, weakness of the bones and tendons, dizziness, hemorrhage during pregnancy, and restless fetal movement.

[0026] Processed Polygonum multiflorum: A processed product of Polygonum multiflorum (the dried tuberous root of Polygonum multiflorum Thunb. of the Polygonaceae family), which is bitter, sweet, astringent, and slightly warm; it enters the liver, heart, and kidney meridians; it nourishes the liver and kidneys, replenishes the essence and blood, blackens the hair, strengthens the tendons and bones, resolves turbidity and lowers lipids; it is used for blood deficiency and sallow complexion, dizziness and tinnitus, premature graying of hair, soreness of the waist and knees, numbness of limbs, metrorrhagia and leukorrhea, and hyperlipidemia.

[0027] Cornus officinalis: The dried mature pulp of Cornus officinalis Sieb. et Zucc., a plant of the Cornaceae family; sour, astringent, and slightly warm; enters the liver and kidney meridians; nourishes the liver and kidneys, astringes and consolidates; used for vertigo and tinnitus, soreness of the waist and knees, impotence and spermatorrhea, enuresis and frequent urination, metrorrhagia and leukorrhea, profuse sweating and collapse, internal heat and thirst.

[0028] Mulberry branch: dried young branch of Morus alba L., a plant of the Moraceae family; slightly bitter, neutral; enters the Liver meridian; slightly bitter, neutral; enters the Liver meridian.

[0029] Eupolyphagasinensis Walker: The dried body of the female Eupolyphagasinensis Walker or Steleophagaplancyi (Boleny), an insect of the family Blattidae; salty, cold; slightly toxic; enters the Liver Channel; dispels blood stasis, repairs tendons and bones; used for traumatic injuries, tendon injuries and fractures, blood stasis and amenorrhea, postpartum abdominal pain due to blood stasis, and lumps and masses.

[0030] "Yinao Tongmai Tang" is a registered preparation of Maoming City Traditional Chinese Medicine Hospital (Yueyaozhi Z05170190). It replenishes qi and blood, nourishes the liver and kidneys, and promotes blood circulation and dredges the meridians. It is mainly used for qi deficiency and blood stasis type stroke. The present invention improves on the old recipe of "Yinao Tongmai Tang". The new recipe follows the following compatibility principle: Astragalus is the monarch drug, earthworm, Millettia reticulata, Salvia miltiorrhiza, safflower and angelica root are all ministerial drugs, Morinda officinalis, Eucommia barbata, processed Polygonum multiflorum and Cornus officinalis are all adjuvant drugs, and mulberry twig and Eucommia ulmoides are all guiding drugs. Astragalus, Angelica root, earthworm, Millettia reticulata, Salvia miltiorrhiza and safflower follow the principle of Buyang Huanwu Tang to replenish qi, nourish blood and dredge the meridians. Morinda twig and Eucommia ulmoides are used to promote blood circulation, remove blood stasis and dredge the meridians, while processed Polygonum multiflorum, Cornus officinalis, Morinda officinalis and Eucommia ulmoides nourish the liver and kidneys. The combination of these drugs has the effects of replenishing qi and promoting blood circulation, nourishing the liver and kidneys, and removing blood stasis and dredges the meridians, and hits the pathogenesis of acute cerebral infarction.

[0031] The use of any of the above-mentioned Chinese medicine compositions and / or extracts thereof in the preparation of drugs for treating stroke should also be within the scope of protection of the present invention.

[0032] Preferably, the stroke is ischemic stroke.

[0033] More preferably, the ischemic stroke is acute ischemic stroke, i.e., acute cerebral infarction.

[0034] Preferably, the extract is an aqueous extract of the traditional Chinese medicine composition.

[0035] The use of any of the above-mentioned Chinese medicine compositions and / or extracts thereof in the preparation of drugs for repairing brain damage caused by stroke should also be within the scope of protection of the present invention.

[0036] Preferably, the stroke is ischemic stroke.

[0037] More preferably, the ischemic stroke is acute ischemic stroke, i.e., acute cerebral infarction.

[0038] Preferably, the extract is an aqueous extract of the traditional Chinese medicine composition.

[0039] Preferably, the repairing of brain damage caused by stroke includes reducing neurological impairment score, reducing cerebral infarction volume and / or reducing the level of inflammatory cytokines in brain tissue.

[0040] More preferably, the inflammatory cytokines include IL-6 and TNF-α.

[0041] The use of any of the above-mentioned Chinese medicine compositions and / or extracts thereof in the preparation of drugs for alleviating neurological dysfunction and / or brain tissue inflammation caused by stroke should also be within the scope of protection of the present invention.

[0042] Preferably, the stroke is ischemic stroke.

[0043] More preferably, the ischemic stroke is acute ischemic stroke, i.e., acute cerebral infarction.

[0044] Preferably, the extract is an aqueous extract of the traditional Chinese medicine composition.

[0045] Preferably, the alleviating neurological impairment caused by stroke includes reducing neurological impairment score, reducing cerebral infarction volume and / or reducing the level of inflammatory cytokines in brain tissue.

[0046] More preferably, the neurological impairment score adopts the Longa scoring method.

[0047] More preferably, the inflammatory cytokines include IL-6 and TNF-α.

[0048] The use of any of the above-mentioned Chinese medicine compositions and / or extracts thereof in the preparation of drugs for improving the efficacy of Western medicine treatment of stroke should also be within the scope of protection of the present invention.

[0049] Preferably, the stroke is ischemic stroke.

[0050] More preferably, the ischemic stroke is acute ischemic stroke, i.e., acute cerebral infarction.

[0051] Preferably, the extract is an aqueous extract of the traditional Chinese medicine composition.

[0052] The use of any of the Chinese medicine compositions and / or their extracts as a synergist for Western medicine treatment in the preparation of a medicament for treating stroke should also fall within the scope of protection of the present invention. The Western medicine treatment is conventional Western medicine treatment for stroke.

[0053] Preferably, the stroke is ischemic stroke.

[0054] More preferably, the ischemic stroke is acute ischemic stroke, i.e., acute cerebral infarction.

[0055] Further preferably, the Western medicine treatment is carried out with reference to the "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2018".

[0056] Preferably, the extract is an aqueous extract of the traditional Chinese medicine composition.

[0057] An oral medicine for treating cerebral stroke, comprising the traditional Chinese medicine composition and / or its extract.

[0058] Preferably, the oral medication is a liquid preparation, including but not limited to decoctions, wines, lotions, tinctures, syrups and oral solutions.

[0059] Preferably, the liquid preparation is a decoction.

[0060] Preferably, the extract is an aqueous extract of the traditional Chinese medicine composition.

[0061] A method for preparing an oral medicine for treating cerebral stroke comprises the following steps: treating a traditional Chinese medicine composition by a water-adding decoction method, collecting a water extract, and adjusting the amount of the crude drugs to 0.200 g / ml to 0.300 g / ml; wherein the traditional Chinese medicine composition is prepared, by weight, from 35 to 45 parts of astragalus, 15 to 20 parts of angelica root, 15 to 20 parts of earthworm, 30 to 38 parts of millettia reticulata, 30 to 38 parts of salvia miltiorrhiza, 10 to 16 parts of safflower, 30 to 38 parts of mori branch, 10 to 16 parts of earthworm, 30 to 38 parts of processed polygonum multiflorum, 15 to 20 parts of cornus officinalis, 15 to 20 parts of morinda officinalis, and 15 to 20 parts of eucommia.

[0062] Preferably, the medicine is made from 35 parts of astragalus, 15 parts of angelica root, 15 parts of earthworm, 30 parts of millettia reticulata, 30 parts of salvia miltiorrhiza, 10 parts of safflower, 30 parts of mulberry twig, 10 parts of earthworm, 30 parts of processed polygonum multiflorum, 15 parts of cornus officinalis, 15 parts of morinda officinalis and 15 parts of eucommia.

[0063] Preferably, the medicine is made from 40 parts of astragalus, 18 parts of angelica root, 18 parts of earthworm, 35 parts of millettia reticulata, 35 parts of salvia miltiorrhiza, 14 parts of safflower, 35 parts of mulberry twig, 14 parts of earthworm, 35 parts of processed polygonum multiflorum, 18 parts of cornus officinalis, 18 parts of morinda officinalis and 18 parts of eucommia.

[0064] Preferably, the medicine is made from 45 parts of astragalus, 20 parts of angelica root, 20 parts of earthworm, 38 parts of millettia reticulata, 38 parts of salvia miltiorrhiza, 16 parts of safflower, 38 parts of mulberry twig, 16 parts of earthworm, 38 parts of processed polygonum multiflorum, 20 parts of cornus officinalis, 20 parts of morinda officinalis and 20 parts of eucommia.

[0065] Preferably, the crude drug amount is adjusted to 0.250 g / ml.

[0066] Preferably, the preparation method comprises the following steps: fully soaking the traditional Chinese medicine composition in water, then fully decocting, solid-liquid separation, collecting the liquid, and adjusting the amount of crude drug to 0.200 g / ml to 0.300 g / ml.

[0067] More preferably, the preparation method includes the following steps: soaking in water equivalent to 4 to 8 times the total mass of the traditional Chinese medicine composition for 1 to 2 hours, then decocting for 2 to 4 hours, filtering, and collecting medicine soup 1; adding water equivalent to 2 to 6 times the total mass of the traditional Chinese medicine composition to the remaining medicinal residue in the previous step, decocting for 1 to 2 hours, filtering, and collecting medicine soup 2; combining medicine soup 1 and medicine soup 2, and concentrating to a crude drug amount of 0.200 g / ml to 0.300 g / ml.

[0068] Further preferably, the preparation method includes the following steps: soaking in water equivalent to 6 times the total mass of the traditional Chinese medicine composition for 1 hour, then decocting for 2 hours, filtering, and collecting medicine soup 1; adding water equivalent to 4 times the total mass of the traditional Chinese medicine composition to the remaining medicinal residue in the previous step, decocting for 1 hour, filtering, and collecting medicine soup 2; combining medicine soup 1 and medicine soup 2, and concentrating to a crude drug amount of 0.200g / ml to 0.300g / ml.

[0069] Further preferably, the preparation method includes the following steps: soaking in water equivalent to 6 times the total mass of the traditional Chinese medicine composition for 1 hour, then decocting for 2 hours, filtering, and collecting medicine soup 1; adding water equivalent to 4 times the total mass of the traditional Chinese medicine composition to the remaining medicinal residue in the previous step, decocting for 1 hour, filtering, and collecting medicine soup 2; combining medicine soup 1 and medicine soup 2, and concentrating to a crude drug amount of 0.250 g / ml.

[0070] Compared with the prior art, the present invention has the following beneficial effects:

[0071] The present invention optimizes the compatibility based on the traditional old prescription to obtain a new Chinese medicine formula, which has the effects of invigorating qi and activating blood circulation, nourishing the liver and kidneys, and removing blood stasis and dredging the meridians. It can repair brain damage caused by stroke, relieve neurological dysfunction and brain tissue inflammation, is safe, has no drug-induced liver damage toxicity, and is combined with Western medicine precision medicine to significantly enhance the therapeutic effect of stroke, improve the patient's clinical symptoms, and promote the recovery of neurological function, providing a new integrated Chinese and Western medicine treatment strategy for clinical practice. DETAILED DESCRIPTION

[0072] The present invention is further described in detail below with reference to specific examples. These examples are intended only to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods used in the following examples are conventional methods unless otherwise specified; the materials and reagents used are commercially available unless otherwise specified.

[0073] Example 1 A Chinese medicine composition for promoting blood circulation and unblocking meridians

[0074] Prescription: 35g Astragalus, 15g Angelica root, 15g Earthworm, 30g Millettia reticulata, 30g Salvia miltiorrhiza, 10g Carthamus tinctorius, 30g Morus alba, 10g Eucommia ulmoides, 30g Prepared Polygonum multiflorum, 15g Cornus officinalis, 15g Morinda officinalis and 15g Eucommia ulmoides.

[0075] Among them, the main medicine is Astragalus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza, safflower and Angelica root, the adjuvant medicines are Morinda officinalis, Eucommia ulmoides, processed Polygonum multiflorum and Cornus officinalis, and the guiding medicines are Mori twig and Scolopendra subspinipes.

[0076] Example 2 A Chinese medicine composition for promoting blood circulation and unblocking meridians

[0077] Formula: 40g Astragalus, 18g Angelica root, 18g Earthworm, 35g Millettia reticulata, 35g Salvia miltiorrhiza, 14g Carthamus tinctorius, 35g Mori branch, 14g Eucommia ulmoides, 35g Prepared Polygonum multiflorum, 18g Cornus officinalis, 18g Morinda officinalis and 18g Eucommia ulmoides.

[0078] Among them, the main medicine is Astragalus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza, safflower and Angelica root, the adjuvant medicines are Morinda officinalis, Eucommia ulmoides, processed Polygonum multiflorum and Cornus officinalis, and the guiding medicines are Mori twig and Scolopendra subspinipes.

[0079] Example 3 A Chinese medicine composition for promoting blood circulation and unblocking meridians

[0080] Formula: 45g Astragalus, 20g Angelica root, 20g Earthworm, 38g Millettia reticulata, 38g Salvia miltiorrhiza, 16g Carthamus tinctorius, 38g Mori branch, 16g Eucommia ulmoides, 38g Prepared Polygonum multiflorum, 20g Cornus officinalis, 20g Morinda officinalis and 20g Eucommia ulmoides.

[0081] Among them, the main medicine is Astragalus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza, safflower and Angelica root, the adjuvant medicines are Morinda officinalis, Eucommia ulmoides, processed Polygonum multiflorum and Cornus officinalis, and the guiding medicines are Mori twig and Scolopendra subspinipes.

[0082] Comparative Example 1 A Chinese medicine composition

[0083] Prescription: 35g Astragalus, 15g Earthworm, 30g Millettia reticulata, 30g Salvia miltiorrhiza, 10g Carthamus tinctorius, 30g Mori branch, 15g Morinda officinalis and 15g Eucommia ulmoides.

[0084] Among them, the main medicine is Astragalus membranaceus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza and Carthamus tinctorius, the adjuvant medicines are Morinda officinalis and Eucommia ulmoides, and the guiding medicine is Morus alba.

[0085] Comparative Example 2: A Chinese medicine composition

[0086] Prescription: 35g Astragalus, 15g Earthworm, 30g Millettia reticulata, 30g Salvia miltiorrhiza, 10g Angelica root, 30g Mori branch, 15g Morinda officinalis and 15g Eucommia ulmoides.

[0087] Among them, the main medicine is Astragalus membranaceus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza and Angelica sinensis root, the adjuvant medicines are Morinda officinalis and Eucommia ulmoides, and the guiding medicine is mulberry branch.

[0088] Comparative Example 3: A Chinese medicine composition

[0089] Prescription: 35g Astragalus, 15g Angelica root, 15g Earthworm, 30g Millettia reticulata, 30g Salvia miltiorrhiza, 10g Carthamus tinctorius, 30g Morus alba, 15g Morinda officinalis and 15g Eucommia ulmoides.

[0090] Among them, the main medicine is Astragalus membranaceus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza, safflower and Angelica sinensis root, the adjuvant medicines are Morinda officinalis and Eucommia ulmoides, and the guiding medicine is mulberry branch.

[0091] Comparative Example 4: a Chinese medicine composition

[0092] Prescription: 35g Astragalus, 15g Earthworm, 30g Millettia reticulata, 30g Salvia miltiorrhiza, 10g Carthamus tinctorius, 30g Morus alba, 30g Prepared Polygonum multiflorum, 15g Morinda officinalis and 15g Eucommia ulmoides.

[0093] Among them, the main medicine is Astragalus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza and safflower, the adjuvant medicines are Morinda officinalis, Eucommia ulmoides and processed Polygonum multiflorum, and the guiding medicine is mulberry branch.

[0094] Comparative Example 5: A Chinese medicine composition

[0095] Prescription: 35g Astragalus, 15g Earthworm, 30g Millettia reticulata, 30g Salvia miltiorrhiza, 10g Carthamus tinctorius, 30g Mori branch, 15g Cornus officinalis, 15g Morinda officinalis and 15g Eucommia ulmoides.

[0096] Among them, the main medicine is Astragalus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza and Carthamus tinctorius, the adjuvant medicines are Morinda officinalis, Eucommia ulmoides and Cornus officinalis, and the guiding medicine is mulberry branch.

[0097] Comparative Example 6: A Chinese medicine composition

[0098] Prescription: 35g Astragalus, 15g Earthworm, 30g Millettia reticulata, 30g Salvia miltiorrhiza, 10g Carthamus tinctorius, 30g Mori branch, 30g Prepared Polygonum multiflorum, 15g Cornus officinalis, 15g Morinda officinalis and 15g Eucommia ulmoides.

[0099] Among them, the main medicine is Astragalus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza and Carthamus tinctorius, the adjuvant medicines are Morinda officinalis, Eucommia ulmoides, processed Polygonum multiflorum and Cornus officinalis, and the guiding medicine is mulberry branch.

[0100] Comparative Example 7: A Chinese medicine composition

[0101] Prescription: 35g Astragalus, 15g Earthworm, 30g Millettia reticulata, 30g Salvia miltiorrhiza, 10g Carthamus tinctorius, 30g Morus alba, 30g Processed Polygonum multiflorum and 15g Cornus officinalis.

[0102] Among them, the main medicine is Astragalus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza and Carthamus tinctorius, the adjuvant medicines are processed Polygonum multiflorum and Cornus officinalis, and the guiding medicine is mulberry branch.

[0103] Comparative Example 8: A Chinese medicine composition

[0104] Prescription: 35g Astragalus, 15g Angelica root, 15g Earthworm, 30g Millettia reticulata, 30g Salvia miltiorrhiza, 10g Carthamus tinctorius, 30g Mori branch, 30g Prepared Polygonum multiflorum, 15g Cornus officinalis, 15g Morinda officinalis and 15g Eucommia ulmoides.

[0105] Among them, the main medicine is Astragalus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza, safflower and Angelica root, the adjuvant medicines are processed Polygonum multiflorum and Cornus officinalis, and the guiding medicine is mulberry branch.

[0106] Comparative Example 9: A Chinese medicine composition

[0107] Prescription: 35g Astragalus, 15g Angelica root, 15g Earthworm, 30g Millettia reticulata, 30g Salvia miltiorrhiza, 10g Carthamus tinctorius, 30g Mori branch, 30g Prepared Polygonum multiflorum, 15g Cornus officinalis, 15g Morinda officinalis and 15g Eucommia ulmoides.

[0108] Among them, the main medicine is Astragalus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza, safflower and Angelica sinensis, the adjuvant medicines are Morinda officinalis, Eucommia ulmoides, processed Polygonum multiflorum and Cornus officinalis, and the guiding medicine is mulberry branch.

[0109] Comparative Example 10 A Chinese medicine composition

[0110] Prescription: 35g Astragalus, 15g Earthworm, 30g Millettia reticulata, 30g Salvia miltiorrhiza, 10g Carthamus tinctorius, 30g Morus alba, 10g Eucommia barbata, 15g Morinda officinalis and 15g Eucommia ulmoides.

[0111] Among them, the main medicine is Astragalus, the ministerial medicines are earthworm, Millettia reticulata, Salvia miltiorrhiza and Carthamus tinctorius, the adjuvant medicines are Morinda officinalis and Eucommia ulmoides, and the guiding medicines are Mori twig and Scolopendra subspinipes.

[0112] Example 4 Preparation method of a Chinese medicine decoction

[0113] According to the Chinese medicine formula, weigh the pieces of each medicinal material, mix them, add water equivalent to 6 times the total weight of the medicinal materials, soak them for 1 hour, then decoct them for 2 hours, filter them, and collect the medicinal soup; then add water equivalent to 4 times the total weight of the medicinal materials to the medicinal residue, decoct them for 1 hour, filter them, and collect the medicinal soup; combine the two medicinal soups and concentrate them to a crude drug amount of 0.250g / ml.

[0114] Application Example 1: Evaluation of therapeutic efficacy in an ischemic stroke animal model

[0115] 1. Construction of Ischemic Stroke Rat Model

[0116] 1. Experimental Animals

[0117] Specific pathogen-free (SPF) grade SD male rats, 6 weeks old, weighing 180-210 g.

[0118] 2. Model construction

[0119] With reference to the existing technology "Ping Xingfeng, Lv Junying, Li Kai, et al. Establishment and evaluation of a rat model of ischemic stroke with phlegm-heat and visceral excess syndrome [J]. Chinese Journal of Tissue Engineering Research, 2025, 29(11): 2301-2309.", the construction of an ischemic stroke rat model mainly includes the following steps:

[0120] Rats were anesthetized by induction with 3% isoflurane at a flow rate of 0.6 L / min and fixed in the supine position on a sterile operating table. The neck was prepared, disinfected, and draped. A longitudinal incision of approximately 1.5 cm was made along the midline of the neck, and the tissue was separated layer by layer to fully expose the right carotid triangle. The common carotid artery, external carotid artery, and internal carotid artery were then separated and exposed in sequence. The proximal ends of the common carotid artery and the proximal ends of the external carotid artery were ligated with sterile sutures. Another suture was taken to the distal end of the internal carotid artery to pull and block blood flow. A small transverse incision was made in the common carotid artery 5 mm away from the bifurcation of the common carotid artery with vascular scissors. A nylon suture was slowly inserted through the incision with ophthalmic forceps. At the same time, the suture was gently released and slowly pushed in to a depth of approximately 18 mm so that the head of the suture reached the origin of the middle cerebral artery. The suture was fixed and the surgical incision was sutured layer by layer.

[0121] 2. Treatment of Ischemic Stroke Rat Model

[0122] 1. Decoction preparation

[0123] The Chinese medicine compositions of Examples 1 to 3 and Comparative Examples 1 to 10 were processed according to the preparation method of Example 4 to prepare corresponding Chinese medicine decoctions.

[0124] 2. Treatment plan

[0125] Ischemic stroke rats were randomly divided into 14 groups, each containing 15 rats, designated as Groups 1 to 14. Groups 1 to 13 were gavaged with 5.0 g of the herbal decoction prepared from the herbal compositions of Examples 1 to 3 and Comparative Examples 1 to 10, respectively. Group 14 was gavaged with an equal amount of drinking water, serving as a control. The decoctions were administered once daily for 10 consecutive days.

[0126] 3. Efficacy evaluation

[0127] (1) Neurological impairment score

[0128] After treatment, the Longa scoring method was used to score the neurological deficits of the rats. The scoring criteria were: 0 points, normal; 1 point, the right forepaw could not be fully extended; 2 points, the rat turned to the right when walking; 3 points, the rat leaned to the right when walking; 4 points, the rat was unable to walk spontaneously and had impaired consciousness.

[0129] (2) Measurement of cerebral infarction volume

[0130] After completing the neurological deficit scoring, the rats were killed, the brain tissue was isolated, and coronal sections were made at 1.5 mm intervals. All brain slices were incubated with TTC staining solution at 37°C in the dark for 10 min, and then photographed. The cerebral infarction volume was measured using ImageJ software.

[0131] (3) Enzyme-linked immunosorbent assay (ELISA)

[0132] The levels of proinflammatory cytokines IL-6 and TNF-α in the supernatant of brain tissue homogenate were detected according to the ELISA kit instructions.

[0133] (4) Statistical processing

[0134] SPSS 26.0 statistical analysis software was used; all measurement data were expressed as mean ± standard deviation. The data were compared between groups using one-way analysis of variance, and pairwise comparisons were performed using t-test. P < 0.05 was considered statistically significant.

[0135] 4. Evaluation results

[0136] Table 1 Treatment results of ischemic stroke rat model

[0137]

[0138] (1) Impact on neurological deficits

[0139] As shown in Table 1, the statistical results of neurological impairment scores showed that compared with group 14, the neurological impairment scores of ischemic stroke rats in groups 1 to 13 were significantly decreased (P<0.05), and the neurological impairment scores of ischemic stroke rats in groups 1 to 3 were further significantly decreased compared with those in groups 4 to 13 (P<0.05).

[0140] (2) Effect on cerebral infarction volume

[0141] The results of TTC staining and the statistical analysis of cerebral infarction volume shown in Table 1 showed that compared with Group 14, the cerebral infarction volume of ischemic stroke rats in Groups 1 to 13 was significantly reduced (P < 0.05), and the cerebral infarction volume of ischemic stroke rats in Groups 1 to 3 was further significantly reduced compared with that in Groups 4 to 13 (P < 0.05).

[0142] (3) Effects on inflammatory cytokine levels in brain tissue

[0143] As shown in Table 1, the statistical results of IL-6 and TNF-α levels in the brain tissues of ischemic stroke rats in groups 1 to 13 were significantly decreased compared with those in group 14 (P<0.05), and the IL-6 and TNF-α levels in the brain tissues of ischemic stroke rats in groups 1 to 3 were further significantly decreased compared with those in groups 4 to 13.

[0144] The above results show that the Chinese medicine composition for promoting blood circulation and unblocking meridians provided by the present invention (Examples 1 to 3) can repair brain damage caused by ischemic stroke, reduce neurological deficit scores, reduce cerebral infarction volume, and reduce the level of inflammatory cytokines in brain tissue, and has neuroprotective effects and reduces neuroinflammation after ischemic stroke.

[0145] Application Example 2: Evaluation of clinical efficacy in ischemic stroke

[0146] 1. Diagnosis of ischemic stroke

[0147] 1. Western medicine diagnosis

[0148] According to the diagnostic criteria for acute ischemic stroke in the "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2018", the main criteria are as follows:

[0149] (1) Acute onset; (2) Focal neurological deficits (weakness or numbness of one side of the face or limbs, speech disorders, etc.), with a few cases presenting with global neurological deficits; (3) The appearance of responsible lesions on imaging or symptoms / signs persisting for more than 24 hours; (4) Exclusion of non-vascular causes; (5) Exclusion of cerebral hemorrhage by brain CT / MRI.

[0150] 2. Traditional Chinese Medicine Diagnosis

[0151] With reference to the stroke diagnosis criteria in the "Stroke Diagnosis and Therapeutic Efficacy Evaluation Criteria" formulated by the National TCM Encephalopathy Emergency Research Collaboration Group of the State Administration of Traditional Chinese Medicine, the main criteria are as follows:

[0152] Main symptoms: hemiplegia, confusion, slurred speech or aphasia, paresthesia on one side of the body, and crooked mouth and tongue.

[0153] Secondary symptoms: headache, dizziness, pupil changes, choking when drinking water, unblinking eyes, and ataxia.

[0154] The disease has an acute onset, often preceded by triggers and often with premonitory symptoms. The age of onset is usually over 40 years old.

[0155] If the disease has two or more main symptoms, or one main symptom and two secondary symptoms, the diagnosis can be confirmed by combining the onset, inducement, precursor symptoms and age; if the above conditions are not met, the diagnosis can also be confirmed by combining the results of imaging examinations.

[0156] Acute phase criteria: onset within 2 weeks, and up to 1 month for internal organs.

[0157] Standards for Qi deficiency and blood stasis syndrome: hemiplegia, crooked mouth and tongue, slurred speech or silence, decreased or absent sensation, pale complexion, shortness of breath and fatigue, spontaneous sweating, dull tongue, white and greasy tongue coating or with teeth marks, and deep and thready pulse.

[0158] 3. Case exclusion

[0159] The exclusion criteria (including inappropriate conditions or exclusion criteria) are as follows: (1) silent cerebral infarction with no symptoms and focal signs; (2) Kubota water drinking test ≥ level 4; (3) patients with mRS grade 5; (4) ischemic stroke due to causes other than atherosclerosis, such as cardiogenic cerebral embolism, arteritis, polycythemia vera, thrombocythemia, sickle cell anemia, thromboembolic thrombocytopenic purpura, disseminated intravascular coagulation, cerebral amyloid angiopathy, Moyamoya disease, intracranial vascular malformation, etc.; (5) patients with severe heart disease, heart failure, liver dysfunction, renal insufficiency, respiratory failure, malignant tumors, gastrointestinal bleeding, etc. at the time of onset, who are not expected to complete the 1-year follow-up; (6) patients with mental illness; (7) patients who cannot take medication on time for other reasons; (8) pregnant and lactating women.

[0160] 2. Clinical Cases

[0161] From January to December 2023, according to the above-mentioned diagnostic method of ischemic stroke, a total of 100 patients with acute cerebral infarction hospitalized in the Department of Neurology of Maoming City Hospital of Traditional Chinese Medicine were included as clinical cases.

[0162] The 100 patients were randomly divided into two groups: 50 in the combined treatment group and 50 in the control group, with an age range of 16 to 80 years. There were no statistically significant differences in gender, age, onset time, and other general information between the two groups (P>0.05), indicating that the two groups were comparable.

[0163] 3. Treatment Methods

[0164] Both groups of patients were given conventional Western medicine treatment for acute cerebral infarction, referring to the "Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2018" for standardized treatment, including symptomatic supportive treatment such as antiplatelet aggregation, anticoagulation, lipid regulation and plaque stabilization, circulation improvement, and control of underlying diseases.

[0165] The Chinese medicine composition of Example 1 was processed according to the preparation method of Example 4 to prepare a Chinese medicine decoction. For patients in the combined treatment group, in addition to conventional Western medicine treatment, they also took the Chinese medicine decoction of Example 1, 100 ml at a time, once a day, for a course of 14 days.

[0166] IV. Efficacy Evaluation

[0167] The efficacy of Western medicine was assessed based on the National Institutes of Health Neurological Disorders Scale (NIHSS).

[0168] The criteria for determining the efficacy of traditional Chinese medicine were evaluated based on the "Stroke Symptom Grading Quantitative Scale" in the "Guidelines for Clinical Research of New Chinese Medicines for the Treatment of Stroke" (Trial Implementation) published by China Medical Science and Technology Press in 2001.

[0169] 1. Criteria for determining the efficacy of Western medicine

[0170] (1) Cure: functional impairment score reduced by 90% to 100%, disability level 0;

[0171] (2) Significantly effective: functional impairment score decreased by 46% to 89%, and the degree of disability was 1 to 3 grades;

[0172] (3) Effective: functional impairment score decreased by 18% to 45%;

[0173] (4) Ineffective: The functional impairment score decreased or increased within 18%.

[0174] 2. Criteria for determining efficacy of TCM syndromes

[0175] (1) Cured: clinical symptoms and signs of TCM disappear or almost disappear, and the syndrome score decreases by ≥95%;

[0176] (2) markedly effective: clinical symptoms and signs of TCM were significantly improved, and the syndrome score was reduced by ≥70%;

[0177] (3) Effective: clinical symptoms and signs of TCM improved, and the syndrome score decreased by ≥30%;

[0178] (4) Ineffective: There is no significant improvement in TCM clinical symptoms and signs, or they may even worsen, and the symptom score decreases by less than 30%.

[0179] 3. Adverse reaction monitoring

[0180] The incidence of drug-induced liver injury (DILI) in patients in the combined treatment group after taking Chinese herbal decoctions was observed.

[0181] The severity of drug-induced liver injury is graded as follows:

[0182] Grade 0 (no liver damage): The patient can tolerate the drug exposure and has no hepatotoxic reaction.

[0183] Grade 1 (mild liver injury): Reversibly elevated serum ALT and / or ALP, TBil < 2.5 x ULN (2.5 mg / dL or 42.75 μmol / L), and INR < 1.5. Most patients can adapt. Symptoms may or may not include fatigue, weakness, nausea, anorexia, right upper abdominal pain, jaundice, pruritus, rash, or weight loss.

[0184] Grade 2 (moderate liver injury): Serum ALT and / or ALP show reversible elevation, TBil ≥ 2.5*ULN, or INR ≥ 1.5 despite no TBil elevation. The above symptoms may worsen.

[0185] Grade 3 (severe liver injury): Elevated serum ALT and / or ALP, TBil ≥ 5*ULN (5 mg / dL or 85.5 μmol / L), with or without INR ≥ 1.5. The patient's symptoms worsen, requiring hospitalization or prolonged hospitalization.

[0186] Grade 4 (ALF): Elevated serum ALT and / or ALP, TBil ≥ 10*ULN (10 mg / dl or 171 μmol / L), or increasing by ≥ 1.0 mg / dl (17.1 μmol / L) per day, INR ≥ 2.0 or PTA < 40%, and concurrent presence of (1) ascites or hepatic encephalopathy; or (2) other organ failure related to DILI.

[0187] Grade 5 (fatal): Death due to DILI, or requiring liver transplantation for survival.

[0188] 4. Statistical analysis

[0189] SPSS 16.0 statistical software was used to analyze the data. t test was used to express the data; the enumeration data were expressed as rate (%) and χ test was used to express the data. 2 Test; rank-sum test was used for ranked data; P < 0.05 indicated that the difference was statistically significant.

[0190] 5. Evaluation results

[0191] Table 2 Results of Western medicine efficacy evaluation

[0192]

[0193] Note: The total effective rate of the combined treatment group and the control group was analyzed by rank sum test, P < 0.05, and the difference between the two groups was statistically significant (Z value = -1.976, P = 0.048).

[0194] Table 3 Results of TCM efficacy evaluation

[0195]

[0196]

[0197] Note: The total effective rate of the combined treatment group and the control group was analyzed by rank sum test, P < 0.05, and the difference between the two groups was statistically significant (Z value = -2.059, P = 0.040).

[0198] As shown in Table 2 and Table 3, no matter according to the evaluation standards of Western medicine or traditional Chinese medicine, the therapeutic effect of the patients in the combined treatment group was significantly improved after taking the Chinese medicine decoction of Example 1 compared with the control group.

[0199] Table 4 Drug-induced liver injury

[0200]

[0201] As shown in Table 4, during the treatment, only two patients in the combined treatment group experienced mild nausea and gastrointestinal reactions. After timely adjustment of the dosage and medication time, the patients were able to tolerate the condition without obvious adverse reactions. Routine blood and urine tests and liver and kidney function tests before and after treatment showed no abnormalities.

[0202] The Chinese medicine compositions of Examples 2 and 3 were also used to treat the clinical cases of the above-mentioned combined Chinese and Western medicine treatment, and achieved treatment results similar to those of the Chinese medicine composition of Example 1 above.

[0203] The above results show that the Chinese medicine composition for promoting blood circulation and unblocking meridians provided by the present invention can be used in combination with Western medicine treatment to assist Western medicine in treating acute cerebral infarction, effectively improve the patient's clinical symptoms, repair brain damage, promote the recovery of neurological function, and significantly improve the efficacy of conventional clinical Western medicine treatment. It has no drug-induced liver damage toxicity, is safe, effective, and feasible, and is worthy of clinical promotion and application.

[0204] Finally, it should be noted that the above embodiments are intended only to illustrate the technical solutions of the present invention and are not intended to limit the scope of protection of the present invention. Those skilled in the art will readily appreciate that other variations or modifications may be made based on the above descriptions and concepts. It is not necessary and impossible to provide an exhaustive list of all possible implementations. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention shall be included within the scope of protection of the claims of the present invention.

Claims

1. Use of a Chinese medicine composition for promoting blood circulation and unblocking collaterals in the preparation of a medicine for treating acute ischemic stroke, characterized in that: The traditional Chinese medicine composition is prepared from 35 to 45 parts of astragalus, 15 to 20 parts of angelica root, 15 to 20 parts of earthworm, 30 to 38 parts of Millettia reticulata, 30 to 38 parts of Salvia miltiorrhiza, 10 to 16 parts of safflower, 30 to 38 parts of mulberry twig, 10 to 16 parts of earthworm, 30 to 38 parts of processed Polygonum multiflorum, 15 to 20 parts of Cornus officinalis, 15 to 20 parts of Morinda officinalis and 15 to 20 parts of Eucommia ulmoides.

2. Use of a Chinese medicine composition for promoting blood circulation and unblocking collaterals in the preparation of a drug for repairing acute brain damage caused by acute ischemic stroke, characterized in that: The traditional Chinese medicine composition is prepared from 35 to 45 parts of astragalus, 15 to 20 parts of angelica root, 15 to 20 parts of earthworm, 30 to 38 parts of Millettia reticulata, 30 to 38 parts of Salvia miltiorrhiza, 10 to 16 parts of safflower, 30 to 38 parts of mulberry twig, 10 to 16 parts of earthworm, 30 to 38 parts of processed Polygonum multiflorum, 15 to 20 parts of Cornus officinalis, 15 to 20 parts of Morinda officinalis and 15 to 20 parts of Eucommia ulmoides.

3. Use of a Chinese medicine composition for promoting blood circulation and unblocking collaterals in the preparation of a medicament for alleviating acute neurological dysfunction and / or brain tissue inflammation caused by acute ischemic stroke, characterized in that: The traditional Chinese medicine composition is prepared from 35 to 45 parts of astragalus, 15 to 20 parts of angelica root, 15 to 20 parts of earthworm, 30 to 38 parts of Millettia reticulata, 30 to 38 parts of Salvia miltiorrhiza, 10 to 16 parts of safflower, 30 to 38 parts of mulberry twig, 10 to 16 parts of earthworm, 30 to 38 parts of processed Polygonum multiflorum, 15 to 20 parts of Cornus officinalis, 15 to 20 parts of Morinda officinalis and 15 to 20 parts of Eucommia ulmoides.

4. The use according to any one of claims 1 to 3, characterized in that The traditional Chinese medicine composition is prepared into a water extract.

5. An oral medication for treating acute ischemic stroke, characterized in that: The oral medicine is prepared from a traditional Chinese medicine composition for promoting blood circulation and unblocking meridians; in parts by weight, the traditional Chinese medicine composition is prepared from 35 to 45 parts of astragalus, 15 to 20 parts of angelica root, 15 to 20 parts of earthworm, 30 to 38 parts of Millettia reticulata, 30 to 38 parts of Salvia miltiorrhiza, 10 to 16 parts of safflower, 30 to 38 parts of mulberry twig, 10 to 16 parts of earthworm, 30 to 38 parts of processed Polygonum multiflorum, 15 to 20 parts of Cornus officinalis, 15 to 20 parts of Morinda officinalis and 15 to 20 parts of Eucommia ulmoides.

6. The oral medicine according to claim 5, characterized in that The oral medicine is a liquid preparation.

7. A method for preparing an oral medicine for treating acute ischemic stroke, characterized in that: The Chinese medicine composition is treated by a water decoction method, and the water extract is collected, and the amount of the crude drugs is adjusted to 0.200g / ml-0.300g / ml. The Chinese medicine composition is prepared by 35-45 parts of astragalus, 15-20 parts of angelica root, 15-20 parts of earthworm, 30-38 parts of Millettia reticulata, 30-38 parts of Salvia miltiorrhiza, 10-16 parts of safflower, 30-38 parts of morus, 10-16 parts of Eucommia barbata, 30-38 parts of processed Polygonum multiflorum, 15-20 parts of Cornus officinalis, 15-20 parts of Morinda officinalis, and 15-20 parts of Eucommia ulmoides.

Images